Research Study

A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants With Advanced Melanoma (LEAP-003)
Principal Investigator 
Sasha Smiljanic

Overview

Body Locations and Systems 
Melanoma
Disorders and Conditions 
Melanoma
ClinicalTrials.gov# 
NCT03820986
Status 
Recruiting
Study Start/End 
Jun 4, 2019 to Apr 30, 2024
Locations 
Lions Gate Hospital
Name/Title 
Valla Sahraei, Research Coordinator
Phone 
604-988-3131 ext.4934
Email Address 
valla.sahraei@vch.ca
Purpose of Study 

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advance melanoma.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.